- Conditions
- HIV Infections
- Interventions
- Dolutegravir/Rilpivirine FDC
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Long Beach, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2353–2376
of 5,570
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Cancer
- Interventions
- cisplatin, fluorouracil, adjuvant therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV/AIDS
- Interventions
- bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), Standard initiation of antiretroviral therapy (ART)
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Omaha, Nebraska
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- REOLYSIN®, Chemotherapy, Gemcitabine, Irinotecan, Leucovorin, 5-fluorouracil, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Metastatic Anaplastic Thyroid Cancer
- Interventions
- durvalumab, tremelimumab, Stereotactic Body Radiotherapy (SBRT)
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Smoking Cessation, Substance-Related Disorders
- Interventions
- Varenicline, Placebo
- Drug
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Asthma
- Interventions
- Fluticasone with salmeterol, Fluticasone HFA, Ipratropium HFA, Albuterol HFA
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Hackensack, New Jersey • New York, New York
- Conditions
- Solid Tumors
- Interventions
- Atezolizumab, Cobimetinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 11
- States / cities
- Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 7 more
- Conditions
- Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Doxorubicin Hydrochloride, Filgrastim, Magnetic Resonance Imaging, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Vinblastine Sulfate
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 711
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 472 more
- Conditions
- Pediatric, Bacterial Infections
- Interventions
- Amoxicillin potassium clavulanate, Amoxicillin potassium clavulanate (Augmentin ES-600)
- Drug
- Lead sponsor
- Kaizen Bioscience Co.
- Industry
- Eligibility
- 3 Months to 24 Months
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- HIV Infections
- Interventions
- Early Treatment with HAART, No treatment, HAART Treatment - standard care
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 20
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Angiosarcoma, Angiosarcoma, Adult
- Interventions
- Vusolimogene Oderparepvec (VO), Pembrolizumab
- Biological · Drug
- Lead sponsor
- Varun Monga, MBBS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- adjuvant therapy, pegylated interferon alfa
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Bevacizumab, Gemcitabine, Carboplatin
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 3
- States / cities
- Palo Alto, California • San Jose, California • Stanford, California
- Conditions
- Advanced Solid Tumors
- Interventions
- TAS-102, Trifluridine
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Attention-deficit/Hyperactivity Disorder
- Interventions
- Guanfacine (sustained release)
- Drug
- Lead sponsor
- Neurology Group of Bergen County, P.A.
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Ridgewood, New Jersey
- Conditions
- CD33 Positive Acute Myelogenous Leukemia
- Interventions
- Antibody Drug Conjugate Chemotherapeutic
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 3 Months and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 142
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 64 more
- Conditions
- Toxoplasmosis, Cerebral, HIV Infections
- Interventions
- Sulfadiazine, Clarithromycin, Atovaquone, Pyrimethamine, Leucovorin calcium
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Miami, Florida • Honolulu, Hawaii + 8 more
- Conditions
- HER2 Positive Solid Tumors
- Interventions
- SBT6050, pembrolizumab, Cemiplimab
- Drug
- Lead sponsor
- Silverback Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Non-cystic Fibrosis Bronchiectasis
- Interventions
- Trikafta
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Talactoferrin, Placebo
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 6
- States / cities
- Duarte, California • Chicago, Illinois • The Bronx, New York + 3 more
- Conditions
- Jaundice, Neonatal, Hyperbilirubinemia, Neonatal
- Interventions
- Phototherapy, Stannsoporfin, Placebo
- Procedure · Drug
- Lead sponsor
- InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
- Industry
- Eligibility
- 1 Hour to 72 Hours
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 18
- States / cities
- Colton, California • San Diego, California • San Francisco, California + 14 more
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- cisplatin, epirubicin hydrochloride, fluorouracil, oxaliplatin, adjuvant therapy, neoadjuvant therapy
- Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio